Reason Evaluation of Initial Treatment Failure in Patients With CAP

Overview

This research is to evaluate the effect of different antibiotics (Moxifloxacin Hydrochloride and Sodium Chloride Injection vs. β-lactam antibiotics for injection +/- Azithromycin for Injection) on the early deterioration or progression (<72 h of treatment) of community acquired pneumonia and to study the effect of the early deterioration or progression on the prognosis of community acquired pneumonia.

Full Title of Study: “Reason Evaluation of Initial Treatment Failure in Patients With Community Acquired Pneumonia”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 31, 2019

Interventions

  • Drug: Moxifloxacin Hydrochloride and Sodium Chloride Injection
    • Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.

Arms, Groups and Cohorts

  • Moxifloxacin group
  • β-lactams group

Clinical Trial Outcome Measures

Primary Measures

  • early deterioration or progression rate
    • Time Frame: 3 days

Participating in This Clinical Trial

Inclusion Criteria

1. Age>=18y. 2. Diagnosed with CAP. 3. Need hospitalization. 4. Receive Moxifloxacin Hydrochloride and Sodium Chloride Injection or β-lactam antibiotics for injection +/- Azithromycin for Injection as initial treatment. 5. Signed informed consent form. Exclusion Criteria:

Patients who meet any of the following criteria will not be included in the study: 1. Pneumonia is aquired more than 48h after admission or the patient was admitted to hospital within 30 days prior to admission. 2. Start antibiotic treatment before admission. 3. Gestational period or suckling period. 4. Admitted to ICU. 5. Immunocompromised patients. 6. Pneumonia is the terminal event of a serious disease. 7. Tuberculosis, lung cancer, non-infectious interstitial lung disease, pulmonary edema, atelectasis, pulmonary embolism, pulmanory eosinophilia, pulmonary vasculitis. 8. Allergic to the antibiotics of the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking Union Medical College Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jun Xu, Dr – Peking Union Medical College Hospital
  • Overall Official(s)
    • Xuezhong Yu, MD, Principal Investigator, Peking Union Medical College Hospital
  • Overall Contact(s)
    • Jun Xu, MD, 010-69159142, xujunfree@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.